Shire PLC (ADR)  

(Public, NASDAQ:SHPG)   Watch this stock  
Find more results for Shire US, Inc
251.81
-0.86 (-0.34%)
Pre-market: 250.75 -1.06 (-0.42%)
Jul 29, 6:18AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 251.02 - 253.10
52 week 107.05 - 258.55
Open 251.84
Vol / Avg. 1,500.00/2.15M
Mkt cap 50.22B
P/E 26.32
Div/yield 0.51/0.24
EPS 9.57
Shares 598.30M
Beta 0.77
Inst. own 5%
Jul 18, 2014
Q2 2014 Shire Plc Earnings Release
Jun 23, 2014
Shire PLC AbbVie Proposal Conference Call
Jun 2, 2014
Shire Plc at Jefferies Global Healthcare Conference
May 14, 2014
Shire Plc at Credit Suisse Stockholm Consumer and Healthcare IR Day
May 7, 2014
Shire Plc at Deutsche Bank Healthcare Conference - Webcast
May 1, 2014
Q1 2014 Shire Plc Earnings Conference Call
May 1, 2014
Q1 2014 Shire Plc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 34.97% 28.69%
Operating margin 22.50% 35.13%
EBITD margin - 40.09%
Return on average assets 18.94% 18.10%
Return on average equity 36.02% 30.94%
Employees 5,338 -
CDP Score - 83 C

Address

Citywest Business Campus 5 Riverwalk, Dublin 24
DUBLIN, ENG
Ireland
+353-1-4297700 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc. Effective May 12, 2014, the Company acquired Lumena Pharmaceuticals Inc.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
James Bowling Interim Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Jeffrey M. Jonas M.D. President - Regenerative Medicine
Age: 61
Bio & Compensation  - Reuters
Tatjana May General Counsel, Company Secretary
Age: 47
Bio & Compensation  - Reuters
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Dominic Blakemore Non-Executive Director
Age: 44
Bio & Compensation  - Reuters
William Burns Non-Executive Independent Director
Age: 65
Bio & Compensation  - Reuters
Steven H. Gillis Ph.D. Non-Executive Independent Director
Age: 60
Bio & Compensation  - Reuters